Results 101 to 110 of about 1,925 (192)

Optimal implementation of an Ontario nirsevimab program for respiratory syncytial virus (RSV) prophylaxis: Recommendations from a provincial RSV expert panel

Human Vaccines & Immunotherapeutics
In June 2024, a group of 12 experts in the respiratory syncytial virus (RSV) field representing a cross-section of healthcare provider types who treat and care for pregnant individuals and infants, assembled to discuss the implementation of a broad ...
Bosco Paes, Vivien Brown, Erin Courtney, Erin Fleischer, Fiona Guy, Eddy Lau, Allan Mills, Julie Toole, Meagan Bardan, Cynthia Wong, Gary Lam, Graeme N. Smith   +11 more
doaj   +1 more source

Efficacy and safety of a single dose of nirsevimab against respiratory syncytial virus infection in infants: a meta-analysis and time-to-event analysis

Italian Journal of Pediatrics
Respiratory syncytial virus (RSV) is one of the causes of lower respiratory tract infections (LRTIs) and related hospitalizations in neonates and infants.
Mohamed Saad Sayed, Mena Ayman Elgendy, Nada Gamil, Hossam Hassan Abdullah, Alaa Alhwary, Rahma Abdulfattah Ibrahim, Sama Hesham Samir, Nada S. Jibril, Hebatullah Abdulazeem, Mohammed Alsabri   +9 more
doaj   +1 more source

Cost-effectiveness analysis of nirsevimab for prevention of respiratory syncytial virus disease among infants in Shanghai, China: A modeling study

Human Vaccines & Immunotherapeutics
Chinese authority approved nirsevimab to prevent respiratory syncytial virus (RSV) in January 2024. We aimed to assess the cost-effectiveness of nirsevimab immunization among infants in Shanghai.
Qiang Wang, Jiajin Wu, Lan Li, Zizhe Guo, Bo Zheng, Suyi Zhang, Cui Xiang, Meng Li, Xuefei Qiao, Xihong Lv, Weibing Wang   +10 more
doaj   +1 more source

Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023–24: a modelling study

International audienceBackground: Respiratory syncytial virus (RSV) is a major cause of hospitalisations and deaths among infants worldwide. France was one of the first countries to implement a national programme (beginning on Sept 15, 2023) for ...
White, Michael, Pontais, Isabelle, Lina, Bruno, Debeuret, Christine, Bloch, Emma, Cauchemez, Simon, Brault, Antoine, Parent Du Châtelet, Isabelle, Enouf, Vincent, Baudemont, Gaëlle, Paireau, Juliette, Rameix-Welti, Marie, Anne, Vaux, Sophie, Casalegno, Jean-Sébastien   +13 more
core   +1 more source

Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024

Respiratory syncytial virus (RSV) is the leading cause of hospitalization among infants in the United States. In August 2023, CDC\u27s Advisory Committee on Immunization Practices recommended nirsevimab, a long-acting monoclonal antibody, for infants ...
Boom, Julie A, Toepfer, Ariana P, Goldstein, Leah, Clopper, Benjamin R, Dawood, Fatimah S, Englund, Janet A, Sahni, Leila C, Schlaudecker, Elizabeth P, Albertin, Christina, Zerr, Danielle M, Schuster, Jennifer E, Michaels, Marian G, Betters, Kristina A, Rohlfs, Chelsea, Stewart, Laura S, Halasa, Natasha B, Selvarangan, Rangaraj, Piedra, Pedro A, McKeever, Erin R, McMorrow, Meredith L, Klein, Eileen J, Musa, Samar, Tannis, Ayzsa, Moline, Heidi L, Staat, Mary Allen, Williams, John V, Weinberg, Geoffrey A, Szilagyi, Peter G, Kalman, Casey, Banerjee, Dithi   +29 more
core   +2 more sources

Nirsevimab: a promising therapy for RSV

The Lancet Microbe, 2022
openaire   +1 more source

Uptake and predictors of newborn respiratory syncytial virus (RSV) immunisation with nirsevimab in Ireland's national pilot programme: a cross-sectional study. [PDF]

BMJ Open
Masukume G, McMorrow A, Dawood I, Rafdhy K, O'Brien F, Desmond C, O'Connell D, Murphy B, Ronan E, Purtill H, Philip RK.   +10 more
europepmc   +1 more source

Impact du nirsevimab sur les hospitalisations pour bronchiolites à VRS au CHU de Clermont-Ferrand durant l'hiver 2023-2024

Contexte : le virus respiratoire syncytial (VRS) est la cause la plus fréquente de bronchiolite chez les nourrissons pouvant causer des atteintes graves allant jusqu’au décès.
Couteau, Lorène
core  

Virus Detection and Hospitalization Rate in Infants With Bronchiolitis After Nirsevimab Introduction: A Retrospective Comparative Two-Season Study. [PDF]

Pediatr Pulmonol
La Regina DP, Spatuzzo M, Bonci E, Nenna R, Petrarca L, Conti MG, Mancino E, Pierangeli A, Antonelli G, Midulla F.   +9 more
europepmc   +1 more source

Impact of a national nirsevimab programme on critical care transport of babies with bronchiolitis: a retrospective observational study. [PDF]

Arch Dis Child
Moore T, Afridi A, Aminudin NH, Gibbons C, Grant O, Fucikova H, Moore CM.   +6 more
europepmc   +1 more source